Recon: Trump preparing order to cut federal health workforce; J&J inks $14B deal with Intra-Cellular

• White House Preparing Order to Cut Thousands of Federal Health Workers (WSJ) (Reuters)
• The CRISPR companies are not OK (STAT)
• Letter to FDA’s Office of Prescription Drug Promotion, CDER (The Partnership for Safe Medicines)
• J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmaker (Endpoints)
• Trump team considers demanding WHO reform, including American in charge (Reuters)
• Trump faces pressure from US industry over China tariff on medicines (Reuters)
• HHS Website Went Down Following Communications Freeze (Bloomberg)

• Argentina says it will withdraw from the World Health Organization, echoing Trump (STAT)
• AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal (Endpoints)
• Africa's top health official presses US to resume health aid (Reuters)
• AstraZeneca shares rise as China probe update reassures (Reuters)
• IHH Healthcare's unit seeks up to $1.25 billion from Japan's Daiichi over Fortis deal (Reuters)
• Modified Dermatology App Now Escapes Ban As German Court Cases Continue (MedTech Insight)
• A $50B Market in Waiting: Medtech Trends To Watch Out For In 2025 In India (MedTech Insight)

• CAR-T cells can arm other immune cells with engineered proteins to fight cancer, study says (STAT)
• Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance (STAT)
• Personalized cancer vaccine shows potential in kidney cancer (STAT)
• Pfizer hires Novartis oncology exec to steer its cancer ambitions (Endpoints)
• Bristol Myers launches fresh round of major cost cuts in bid to get ahead of patent cliff (Endpoints)
• AffyImmune’s layoffs; Henlius makes a biosimilar deal with Dr. Reddy’s (Endpoints)
• Lilly's profit forecast bring investors some relief amid Zepbound miss (Reuters)
• Becton looks to separate biosciences and diagnostic solutions after upbeat quarterly results (Reuters)
• Wegovy maker Novo Nordisk says surging growth driving emissions higher (Reuters)
• Bausch + Lomb Sale Stumble Frustrates Bausch Health Investors (Bloomberg)

• New Teladoc, same acquisition strategy (STAT)
• Digital health dealmaking is heating up (Endpoints)
• Siemens Healthineers says it would welcome stake reduction by Siemens (Reuters)
• Zimmer touts ASC opportunity with Paragon 28 purchase (MedTech Dive)
• AHA joins call for Trump to exempt devices from import tariffs (MedTech Dive)
• Medtronic’s Orleigh Bogle on changing the culture of surgical training (MedTech Dive)
• Boston Scientific closes its year of PFA on a high note (MedTech Dive)
• Illumina placed on China’s unreliable entity list (MedTech Dive)
• Pulse Biosciences names new CFO, continuing string of C-suite changes (MedTech Dive)
• Legal Overview Of MDR’s ‘Overly Broad And Vague Article 10a’ (MedTech Insight)
• US FDA’s Absence Raises Concerns In International Standards Development (MedTech Insight)

• USDA milk testing shows different strain of H5N1 bird flu in Nevada dairy herds (STAT)
• We are all complicit in the big lie of health insurance (STAT)
• FDA clinical trial inclusivity guidelines will be back (STAT)
• What happens when a rare disease drug seems to work, but the health care system doesn’t? (STAT)
• FDA Tissue Biopsy Draft Guidance Could Boost Liquid Biopsy Adoption In Clinical Trials (MedTech Insight)